Trinity Biotech - TRIB Stock Forecast, Price & News

Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on TRIB shares. StockNews.com started coverage on shares of Trinity Biotech in a research note on Tuesday, August 9th. They issued a "buy" rating on the stock. TheStreet lowered shares of Trinity Biotech from a "c-" rating to a "d" rating in a research note on Tuesday, July 5th.

Trinity Biotech Stock Down 2.1 %

Shares of NASDAQ:TRIB traded down $0.03 during mid-day trading on Tuesday, hitting $1.38. The company's stock had a trading volume of 17,996 shares, compared to its average volume of 39,646. Trinity Biotech has a one year low of $0.86 and a one year high of $3.05. The company's fifty day simple moving average is $1.33 and its 200-day simple moving average is $1.21.

Trinity Biotech (NASDAQ:TRIB - Get Rating) last released its quarterly earnings data on Thursday, June 30th. The company reported ($0.08) earnings per share for the quarter. Trinity Biotech had a negative return on equity of 347.92% and a negative net margin of 15.10%. The firm had revenue of $18.78 million for the quarter.